UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,232	10/03/2006	Mark L. Witten	12241-021-999	2163
20583 JONES DAY	7590 12/19/200	8	EXAMINER	
222 EAST 41S			LUKTON, DAVID	
NEW YORK, NY 10017			ART UNIT	PAPER NUMBER
			1654	
			MAIL DATE	DELIVERY MODE
			12/19/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comments	10/553,232	WITTEN, MARK L.				
Office Action Summary	Examiner	Art Unit				
	DAVID LUKTON	1654				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>10 C</u>	October 2008					
<i>'</i>	/					
	- 11					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-16</u> is/are pending in the application	4) Claim(s) 1-16 is/are pending in the application.					
4a) Of the above claim(s) is/are withdra	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are allowed.						
7) Claim(s) is/are objected to.						
·	election requirement					
8)⊠ Claim(s) <u>1-16</u> are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 10/14/05, 1/18/06, 3/13/08.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	(PTO-413) ate				

Art Unit: 1654

Applicants' elections are acknowledged:

- a) the peptide is [Sar⁹, MetO₂¹¹]substance P;
- b) the route of administration is aerosol administration;
- c) the disease feature to be mitigated is pulmonary alveolar macrophage number

However, upon a more careful review of the claims, a second restriction requirement is now imposed, as set forth below.

. .

Restriction to one of the following inventions is required under 35 U.S.C. §121:

- I. Claims 1-9, drawn to a method of treating a patient who is afflicted with acute respiratory distress syndrome (ARDS) or severe acute respiratory syndrome (SARS).
- II. Claims 10-16, drawn to a method of protecting a "first" subject from developing ARDS or SARS, wherein the "first" subject has been or will soon be exposed to a "second" subject, wherein the "second" subject is stricken with ARDS or SARS.

The claimed inventions are distinct. Group II is primarily concerned with transmission of a viral infection. While Group I would include lung disease caused by a virus, it also includes respiratory disorders caused by smoke inhalation.

Applicants are required under 35 U.S.C. §121 to elect species (as follows) for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable:

Art Unit: 1654

- a) a specific peptide to be administered;
- b) the route of administration;
- c) a specific disease feature to be mitigated (e.g., neutrophil number, or clara cell necrosis);
- d) one of the following: (i) SARS or (ii) ARDS
- e) in the event that ARDS is elected, further election of one of the following is required: (i) the ARDS is caused by smoke inhalation, or (ii) the ARDS is caused by respiratory viral illness, or (iii) the ARDS is caused by acute trauma, or (iv) the ARDS is caused by stomach aspiration

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. _103 of the other invention.

4

Art Unit: 1654

Those references stricken from the IDS were not received.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached at (571)272-0562. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

/David Lukton/

Primary Examiner, Art Unit 1654